Thermo Fisher Scientific Inc (TMO): Price and Financial Metrics


Thermo Fisher Scientific Inc (TMO)

Today's Latest Price: $517.22 USD

1.38 (0.27%)

Updated Jan 21 1:17pm

Add TMO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

TMO Stock Summary

  • With a market capitalization of $204,445,544,925, Thermo Fisher Scientific Inc has a greater market value than 99.19% of US stocks.
  • Thermo Fisher Scientific Inc's stock had its IPO on September 1, 1987, making it an older stock than 91.54% of US equities in our set.
  • Price to trailing twelve month operating cash flow for TMO is currently 29.79, higher than 83.87% of US stocks with positive operating cash flow.
  • If you're looking for stocks that are quantitatively similar to Thermo Fisher Scientific Inc, a group of peers worth examining would be KO, ABT, T, PEP, and PDD.
  • TMO's SEC filings can be seen here. And to visit Thermo Fisher Scientific Inc's official web site, go to www.thermofisher.com.

TMO Stock Price Chart Interactive Chart >

Price chart for TMO

TMO Price/Volume Stats

Current price $517.22 52-week high $532.57
Prev. close $515.84 52-week low $250.21
Day low $512.75 Volume 613,402
Day high $520.00 Avg. volume 1,756,110
50-day MA $475.14 Dividend yield 0.17%
200-day MA $414.58 Market Cap 204.99B

Thermo Fisher Scientific Inc (TMO) Company Bio


Thermo Fisher Scientific provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company was founded in 1956 and is based in Waltham, Massachusetts.

TMO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$517.22$248.96 -52%

We started the process of determining a valid price forecast for Thermo Fisher Scientific Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Thermo Fisher Scientific Inc ranked in the 35th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Thermo Fisher Scientific Inc, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is 5.96; that's higher than 57.66% of US stocks in the Healthcare sector that have positive free cash flow.
  • 91% of the company's capital comes from equity, which is greater than 74.38% of stocks in our cash flow based forecasting set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-53%
1%-52%
2%-52%
3%-51%
4%-51%
5%-50%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as TMO, try RGEN, A, IART, MD, and BIO.


TMO Latest News Stream


Event/Time News Detail
Loading, please wait...

TMO Latest Social Stream


Loading social stream, please wait...

View Full TMO Social Stream

Latest TMO News From Around the Web

Below are the latest news stories about Thermo Fisher Scientific Inc that investors may wish to consider to help them evaluate TMO as an investment opportunity.

Drugs of Abuse Testing Devices Market 2021- Impact of COVID-19 | Biggest Innovations and Future Technologies by F. Hoffmann La-Roche, Siemens Healthineers, Thermo Fisher Scientific, Alere, Shimadzu, Laboratory Corporation of America Holdings, Dragerwerk,

Drugs of abuse testing are an advanced technique for detecting an illegal or prescribed substance in the sample such as hair, blood, urine, saliva, or sweat. This process includes the screening test followed by the identification of drugs present in

OpenPR | January 20, 2021

UV/Visible Spectroscopy Market worth $1.2 billion by 2025 - Leading Key Players are Shimadzu Corporation (Japan), Agilent Technologies (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US)

According to the new market research report "UV/Visible Spectroscopy Market by Instrument Type (Single-Beam, Dual-Beam), Application (Academic Application, Industrial Application), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes) - Global Forecast to 2025", published by MarketsandMarkets™, the market

OpenPR | January 20, 2021

Thermo Fisher acquires Mesa Biotech in $450M tuck-in deal

Thermo Fisher Scientific Inc. has inked a definitive agreement to acquire Mesa Biotech Inc., a privately held molecular diagnostics company with a point-of-care (POC) platform, for approximately $450 million in cash. The scientific instruments and testing giant said it will pay an additional $100 million in cash upon the completion of certain milestones. The planned acquisition will expand Thermo Fisher’s franchise of diagnostic test options with a novel platform that enables nucleic acid polymerase chain reaction (PCR) testing at the point of care.

BioWorld | January 19, 2021

Global Diagnostic Tests Market 2021-2027:Size,share,Opportunities, Impact of Drivers, Key Vendors-ABBOTT, Danaher, BD, Thermo Fisher Scientific Inc., ACON Laboratories Inc., Hemosure, Inc

Diagnostic Tests market report provides historical data along with future forecast and detailed analysis for the market on a global and regional level. This analysis gives an examination of various segments that are relied upon to witness the quickest development

OpenPR | January 19, 2021

Thermo Fisher Scientific to Acquire Point-of-Care Molecular Diagnostics Provider Mesa Biotech

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has entered into a definitive agreement to acquire Mesa Biotech, Inc., a privately held molecular diagnostic company, for approximately $450 million in cash. Under the terms of the agreement, Thermo Fisher will pay up to an additional $100 million in cash upon the completion of certain milestones following the close of the transaction.

Yahoo Finance | January 19, 2021

Read More 'TMO' Stories Here

TMO Price Returns

1-mo 11.18%
3-mo 7.77%
6-mo 27.40%
1-year 52.47%
3-year 142.14%
5-year 288.23%
YTD 11.04%
2020 43.72%
2019 45.55%
2018 18.21%
2017 35.03%
2016 -0.12%

TMO Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TMO Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9641 seconds.